KASMEJ

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Index
Original Article
The effects of MDR-1 gene polymorphisms on the clinical course of chronic hepatitis B infection
Aims: Chronic HBV infection is associated with high morbidity and mortality rate due to increased risk of hepatic cirrhosis and hepatocellular cancer. Treatment modilities and resistance is currently investigated. Several mechanisms were underlying in drug resistance. P-glycoprotein (P-gp), the product of multidrug resistance gene (MDR-1), is well-known mechanism of MDR phenotype. MDR gene C1236T polymorphism is associated with decreased p-gp function. The mutation of MDR gene can affect the clinical course of disease and response rate to treatment. It was aimed to investigate the relationship between MDR gene polymorphism and clinical course and treatment responses in chronic HBV infection in our study.
Methods: A total of 90 (male/female:69/21) patients with chronic HBV infection under Lamivudine treatment was enrolled in this study. Mean ages were 49.8±12.6 (range:22-75) years. The patients were categorized as: Treatment responded (group 1: HBV-DNA is negative at 24th week) and treatment refractory (group 2: HBV-DNA is still positive after 24th week). Group 1 was consisted of 51 (M/F: 38/13) and group 2 was consisted of 39 (M/F: 31/9) patients. There was no significant difference between ages and genders of two groups. Histologic activity indexes (HAI), total bilirubin, AST and ALT levels, HBV-DNA titers were significantly higher in the patients in group 2 than group 1 (p<0.05).
Results: Genotype distributions; homozygous CC genotype was in 8 (15.7%),heterozygous CT genotype was in 37 (%72.5), homozygous TT genotype wasin 6 (11.8%) in patients at group 1. Homozygous CC genotype was in 13 (33.3%), heterozygous CT genotype was in 21 (53.8%), homozygous TT genotype was in 5 (12.8%) in patients at group 2. CC genotype was more common in group 2 than group 1 (p=0.044). C and T alleles’ frequencies in the group 1 and 2 were 51.96% and 60.26%, 48.04% and 39.74%, respectively (p>0.05). The patients with YMDD mutation positive at group 2 (n:11), 5 (45%) had have CC genotype, 5 (45%) had have CT, 1 (9%) had have TT genotype.The patients with YMDD mutation negative at group 2 (n:8), 3 (37%) patients had have CC and 5 (63%) patients had have CT genotype. CC genotype was more common in the patients with YMDD mutation positive than group 1 (p=0.043). Moreover, CC genotype was more common in the patients with HBV-DNA positive at 12nd month of Lamivudine treatment than group 1 (p=0.042).
Conclusion: Consequently; MDR-1 and p-gp polymorphisms are important factors in the clinical course of chronic HBV infection and may influence the treatment responses. In the current study, it was found that the CC genotype of MDR-1 gene C1236T was more common in the patients with lamivudine resistant HBV infection.


1. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet. 2003;362(9401):2089-2094.
2. American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology. 1995;108(925): 6.
3. Marzolini C, Kim RB. Polymorhisms in human MDR1 (p-glycoprotein);Recent advances and clinical relevance Clin Pharmacol Ther. 2004;75(1):13-33.
4. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequencyof the C3435T mutation in exon 26 is significantly influenced by ethnicity.Pharmacogenetics. 2001;11(3): 217-21.
5. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in humanplacenta: Relation to genetic polymorphism of the multidrug resistance(MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297(3):1137-1143.
6. Wandel C, Kim R.B, Kajiji S, et al. P-glycoprotein and cytochrome P–450 3A inhibition; KHU0Y dissociation of inhibitory potencies. Cancer Res. 1999;59(16):3944–3948.
7. Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol. 2006;78(10):1276-1283.
8. Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol. 2004;42(9):3932-3936.
9. Yurdaydın C, Bozkaya H, Çetinkaya H, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg (-) chronic hepatitis B. J Viral Hepat. 2005;12(3):262-268.
10. Sönmez E. Antiviral direnç monitorizasyonu ve klinik yararı. Klimik Derg. 2001;14(2):66-70.
11. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine resistant hepatitis B virus polymerase gene variants. J Virol Methods. 1999;83(1-2):181-187.
12. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11(4):869-892.
13. Pallier C, Castéra L, Soulier A et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80(2):643-653.
14. Chang UI, Lee YC, Wie SH, et al. Evolution of viral load and changes of polimerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. J Med Virol. 2007;79(7):902-910.
15. Liu K, Hou W, Zumbika E, et al. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ SCIENCE B. 2005;6:1182-1187.
16. Si Ahmed N, Tavan D, Pichoud C, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology. 2000;32(5):1078- 1088.
17. Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol. 2002;37(6):824-830.
18. Tang K, Ngoi SM, Gwee PC, et al. Disitnct haplotype profiles and strong linkage disequilibirium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437-450.
19. Sakaeda T. MDR1 genotype-related pharmacogenetics: fact or fiction? Drug Metab Pharmacokinet. 2005;20(6):391-414.
20. Schwab, Eichelbaum M, Fromm MF. Genetic polymorhisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43(1):285- 307.
21. Tsuruo T. Lida H. Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967- 1972.
22. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia. 2000;14(3):467-473.
23. Takeshita H, Gebhardt MC, Springfield DS, et al. Experimental modelsfor the study of drug resistance in osteosarcoma: P-glycoprotein-positive,murine osteosarcoma cell lines. J Bone Joint Surg Am. 1996;78(3):366-375.
24. Tischler D, Weinberg K, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36(1):1-6.
25. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147- 153.
26. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDRl gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124(1):26-33.
27. Lee W, Lochart C, Richard B, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. The Oncologist. 2005;10(2):104-111.
28. Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicity-relatedpolymorphisms and haplotypes in the human ABCB1 gene.Pharmacogenomics. 2007;8(1):29-39.
29. Fellay J, Mariolini C, Meaden ER, et al. Swiss HIV Cohort Study. Responseto antiretroviral treatment in HIV- 1 -infected individuals with allelicvariants of the multidrug resistance transporter 1: A pharmacogeneticsstudy. Lancet. 2002; 359(9300):30-36.
30. Timucin M, Alagozlu H, Ozdemir S, Ozdemir O. Association betweenABCB1 (MDR1) gene polymorphism and unresponsiveness combinedtherapy in chronic hepatitis C virus. Hepat Mon. 2013;13(4):e7522.
Volume 3, Issue 1, 2023
Page : 1-5
_Footer